More than 8,000 women participated in the NIH-funded study, which was conducted in part at UNC. The vaccine was partially effective at preventing herpes simplex virus type 1 (HSV-1), but did not protect women from herpes simplex virus type 2 (HSV-2).
First results from ongoing Phase III trial show malaria vaccine candidate, RTS,S* reduces the risk of malaria by half in African children aged 5 to 17 months
The University of North Carolina at Chapel Hill enrolled 1,600 children at the study site in Lilongwe, Malawi.
This is the first study to demonstrate active replication of HIV virus in a cell type other than immune T cells and which may help to predict patients at greatest risk for HIV dementia.
A new study led by researchers at the University of North Carolina at Chapel Hill finds that there may be a limit to how early the therapy, known as HAART, should start.
The UNC Center for AIDS Research (CFAR) plays an active role in education and outreach, and provides developmental grant awards to support new ideas and new investigators in HIV/AIDS research.
July 13, 2011 – A new study by investigators from the University of North Carolina at Chapel Hill School of Medicine has confirmed the existence of a “trial effect” in clinical trials for treatment of HIV and also shows that effect has diminished over time.
July 11, 2011 -- Researchers at the University of North Carolina at Chapel Hill have been awarded a $32 million, five-year federal grant to develop ways to cure people with HIV by purging the virus hiding in the immune systems of patients taking antiretroviral therapy. Tackling this latent virus is considered key to a cure for AIDS.
July 8, 2011 – Adaora Adimora, MD, MPH, professor of medicine in the Division of Infectious Diseases in the Department of Medicine at UNC, has been appointed to the Advisory Council of the National Institute of Allergy and Infectious Diseases.
In comparing data from experiments with Hepatitis A and Hepatitis C, the research team found that Hepatitis A virus, which causes only acute, self-limited disease, is more efficient at inhibiting the host’s interferon response, and that the virus can actually linger in the body for almost a year.
UNC researchers have been awarded the prestigious Charles C. Shepard Science Award in the category of Prevention and Control by the Centers for Disease Control and Prevention for their paper titled, “Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.”
A new study from the University of North Carolina at Chapel Hill School of Medicine further validates the use of humanized BLT mice in the fight to block HIV transmission.
UNC-led international study shows early treatment with antiretroviral therapy prevents HIV transmission
A research study led by the University of North Carolina at Chapel Hill has made a major discovery in the effort to halt the spread of HIV, the virus that causes AIDS.
The USAID-funded Lilongwe Relief Fund Trust of Malawi (LMRFT), in collaboration with the University of North Carolina (UNC) at Chapel Hill and several other public and private partners, has begun implementing the Safeguard the Family Project, which is aimed at decreasing mother-to-child transmission of HIV and reducing maternal and infant mortality.
The 18th Annual Conference on Retroviruses and Opportunistic Infections (CROI) wrapped up in Boston, Massachusetts, earlier this month, and UNC had a strong presence at this year’s conference.
The University of North Carolina at Chapel Hill School of Medicine has launched a new program which will expand both the research and clinical capabilities of the University.
UNC researchers Jeff Dangl, PhD, and P. Frederick Sparling, MD, have been named fellows of the American Academy of Microbiology
Fellows are elected in recognition of excellence, originality and creativity in the microbiological sciences, and have built exemplary careers in basic and applied research, teaching, clinical and public health, industry or government service.